Trump Executive Order Medicare has been pressed by drug industry behind the change in Medicare discussion
A new executive order signed on Tuesday directed Congress to change the original provision of the law to allow the Medicare Drug to discuss the price of Medicare Drugs, which would fix one of the largest allegations of the drug industry.
This order calls the industry the “Pill Penalty” of the inflation decrease, where small molecules – usually pillows – the price of Medicare drugs soon faces the price of the drug.
Small molecules are eligible for selection in the discussion program of the drug seven years after the approval of the Food and Drug Administration (FDA). After the two -year discussion period, the new price came into effect for nine years.
Biologics are eligible for elections after 11 years of approval, then after two years of discussion period, 13 years of new prices come into force.
“This imbalance further enhances the enthusiasm that is often often pressed to invest larger molecules than small molecules alternatives, which are often applicable to a wide population and apply to various types of conditions,” an administration official told reporters on Tuesday.
Industrial groups similarly argue that the law sends a signal to researchers that develop small molecules is not suitable for risk to develop drugs.
This change is not the administration itself, so it has directed Robert F. Kennedy Jr., Secretary of Health and Human Services (HHS) to work with the Congress to simplify it. There are already laws in the House and the Senate that will achieve that goal.
The drug industry lobbyists have been trying to change “Pill Penalty” since the law was passed.
The guidelines contained in a long executive order touched on the issue of multi -healthcare confirming that Trump will keep one of the Biden administration’s signature health policies. Specifically shedding, officials said that the order would further save the Medicare beneficiaries.
Furthermore, Trump’s order aims to restore its first term health agenda components, including insulin and epinephrin discounts for low -income people and low -income people to import prescription drugs from Canada.
The order attempts to align the payment rates, even if the order costs to provide payment rates for the hospital drug. Hospitals often get heavy discount drugs, officials said in the call, sometimes less than 35 percent less than the money paid by Medicare.
Excluding the prescription drugs, the order ordered the HHS to investigate a policy known as a site-neutral payment, for which the service is not provided, the same service will be required to provide the same rate for the same service.
To prevent hospitals from getting more money from Medicare for methods that can be done in less expensive settings such as physician’s office or ambulatory surgical center.
It is not clear whether HHS can implement a site-neutral policy by making rules without any law. Congress has been looking for site-neutral payments for years, but the hospitals have long been an attempt to equate the rate of payment, this national move will damage rural suppliers and those who depend on the high proportions of Medicare and Medicaid will damage them.
